The latest announcement is out from Medicenna Therapeutics Corp ( (TSE:MDNA) ).
Medicenna Therapeutics Corp announced that it will present updates from its Phase 1/2 ABILITY-1 Study of MDNA11 and pre-clinical data for MDNA113 at the upcoming American Association for Cancer Research Annual Meeting 2025. These presentations highlight Medicenna’s progress in developing innovative cancer therapies, potentially enhancing its position in the immunotherapy market and offering new treatment options for patients with advanced solid tumors.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company that focuses on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. The company is engaged in creating advanced therapies targeting cancer and autoimmune diseases, with products like MDNA11, a long-acting IL-2 Superkine, and bizaxofusp, an IL-4 Empowered Superkine, which has received FastTrack and Orphan Drug status from the FDA and EMA.
YTD Price Performance: -37.74%
Average Trading Volume: 69,767
Technical Sentiment Signal: Buy
Current Market Cap: C$77.43M
See more data about MDNA stock on TipRanks’ Stock Analysis page.